CDC42 (P60953) variants and mutations
CDC42 (also known as P60953) is a human protein-coding gene encoding a cell division control protein 42 homolog protein. It acts as a molecular switch controlling actin organization, cell polarity, migration, vesicle trafficking, and multiple developmental signaling pathways. Germline dysregulating variants can cause Takenouchi-Kosaki syndrome and related neurodevelopmental disorders with hematologic and immune abnormalities. This analysis covers 319 CDC42 variants and mutations. Of these, 90% have computational variant effect predictions. Disease context includes macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptoda, hereditary disease, and hemophagocytic syndrome. Example CDC42 variants include Q2K, Q2Q, and T3K.
Variant analysis overview
- Gene: CDC42
- Protein: P60953
- UniProt accession: P60953
- Organism: Homo sapiens
- Variants analyzed: 319
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 145 unspecified-consequence records; 86 missense variants; 63 synonymous variants; 5 splice-region variants; 11 frameshift variants; 5 stop-gained variants; 4 substitution
- Prediction scores: 286 variants have prediction scores (90% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptoda, hereditary disease, hemophagocytic syndrome, exanthem, Skin rash, neurodevelopmental disorder, diverticular disease, Neurodevelopmental abnormality, Abnormal facial shape, Abnormality of the immune system, Postnatal growth retardation, Abnormality of blood and blood-forming tissues.
Protein structure and variant hotspots
- Protein features: 25 binding sites; 7 post-translational modification sites.
- PTM context: 7 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CDC42 variants
Examples include Q2K, Q2Q, T3K, T3S, T3A, I4M, I4S, I4V. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Q2K (p.Gln2Lys), gnomAD 1-22078482-C-A, CADD 22.10, PolyPhen-2 0.00
- Q2Q (p.Gln2Gln), rs774271691, gnomAD 1-22078484-G-A, CADD 10.50
- T3K (p.Thr3Lys), NCI-TCGA TCGA novel, MetaLR 0.37, MetaSVM -0.23, Variant assessed as somatic; moderate impact.
- T3S (p.Thr3Ser), gnomAD 1-22078485-A-T, CADD 21.90, PolyPhen-2 0.02
- T3A (p.Thr3Ala), gnomAD 1-22078485-A-G, CADD 22.50, PolyPhen-2 0.01
- I4M (p.Ile4Met), gnomAD rs1385478360
- I4S (p.Ile4Ser), Ensembl rs1019874387
- I4V (p.Ile4Val), cosmic curated COSV10021, MetaLR 0.19, MetaSVM -0.68
- V7G (p.Val7Gly), cosmic curated COSV59663
- V7V (p.Val7Val), gnomAD 1-22078499-T-G, CADD 11.20
- V9L (p.Val9Leu), Ensembl rs1645575083, CADD 22.80, PolyPhen-2 0.05
- V9V (p.Val9Val), gnomAD 1-22078505-G-T, CADD 8.25
- G10D (p.Gly10Asp), gnomAD 1-22078507-G-A, CADD 27.60, PolyPhen-2 1.00
- G10G (p.Gly10Gly), rs375924804, gnomAD 1-22078508-C-T, CADD 5.71
- D11H (p.Asp11His), cosmic curated COSV59661
- D11N (p.Asp11Asn), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, NCI-TCGA Cosmic COSV5966, MetaLR 0.76, MetaSVM 0.79, Variant assessed as somatic; moderate impact.
- G12V (p.Gly12Val), cosmic curated COSV59663, MetaLR 0.79, MetaSVM 0.91
- A13P (p.Ala13Pro), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, Variant assessed as somatic; moderate impact.
- A13V (p.Ala13Val), cosmic curated COSV10021
- V14F (p.Val14Phe), NCI-TCGA TCGA novel, MetaLR 0.86, MetaSVM 1.04, Variant assessed as somatic; moderate impact.
- G15C (p.Gly15Cys), cosmic curated COSV59663
- G15V (p.Gly15Val), cosmic curated COSV59662, MetaLR 0.98, MetaSVM 0.97
- K16R (p.Lys16Arg), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, Variant assessed as somatic; moderate impact.
- T17I (p.Thr17Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T17K (p.Thr17Lys), NCI-TCGA TCGA novel, MetaLR 0.88, MetaSVM 1.07, Variant assessed as somatic; moderate impact.
- T17T (p.Thr17Thr), rs775718828, gnomAD 1-22078529-A-G, CADD 12.30
- C18S (p.Cys18Ser), cosmic curated COSV59663, MetaLR 0.14, MetaSVM -0.89
- C18C (p.Cys18Cys), gnomAD 1-22078532-T-C, CADD 13.70
- L19L (p.Leu19Leu), gnomAD 1-22078535-C-T, CADD 10.40
- L20P (p.Leu20Pro), cosmic curated COSV10732, MetaLR 0.84, MetaSVM 0.96
- L20L (p.Leu20Leu), rs965447224, gnomAD 1-22078536-C-T, CADD 12.70
- L20V (p.Leu20Val), gnomAD 1-22078747-C-G, CADD 15.80
- L20Q (p.Leu20Gln), gnomAD 1-22078748-T-A, CADD 18.20
- I21T (p.Ile21Thr), rs1064795845, ClinGen CA16617069, ClinVar RCV000481008, ClinVar RCV000601771, AlphaMissense 0.99, MetaLR 0.62, Likely pathogenic, not provided
- S22S (p.Ser22Ser), rs1284703979, gnomAD 1-22078544-C-T, CADD 12.60
- Y23* (p.Tyr23Ter), cosmic curated COSV10942
- Y23C (p.Tyr23Cys), rs797044916, ClinGen CA204780, ClinVar RCV000190749, ClinVar RCV001093410, AlphaMissense 0.99, MetaLR 0.77, Pathogenic, Neurodevelopmental disorder; Inborn genetic diseases; Fetal anomalies with a lik
- Y23N (p.Tyr23Asn), rs1645575312, ClinGen CA338912152, ClinVar RCV001268618, Ensembl rs1645575312, AlphaMissense 1.00, MetaLR 0.83, Likely pathogenic, not provided
- T24A (p.Thr24Ala), cosmic curated COSV59662
- T24K (p.Thr24Lys), cosmic curated COSV10453, CADD 25.80, PolyPhen-2 0.59
- T24P (p.Thr24Pro), rs2124005167, ClinGen CA338912170, ClinVar RCV002211080, Ensembl rs2124005167, AlphaMissense 0.99, MetaLR 0.75, Likely pathogenic, not provided
- N26N (p.Asn26Asn), rs1645575380, gnomAD 1-22078556-C-T, CADD 8.80
- K27R (p.Lys27Arg), gnomAD 1-22078558-A-G, CADD 23.00, PolyPhen-2 0.05
- K27E (p.Lys27Glu), gnomAD 1-22078762-A-G, CADD 18.30
- K27K (p.Lys27Lys), gnomAD 1-22078764-A-G, CADD 19.90
- F28F (p.Phe28Phe), gnomAD 1-22078562-T-C, CADD 13.70
- P29P (p.Pro29Pro), rs760835408, gnomAD 1-22078565-A-G, CADD 12.80
- S30L (p.Ser30Leu), cosmic curated COSV59661, CADD 23.30, PolyPhen-2 0.08
- S30S (p.Ser30Ser), rs368993116, gnomAD 1-22078568-G-A, CADD 4.19
- E31E (p.Glu31Glu), gnomAD 1-22078571-A-G, CADD 10.20
- V33A (p.Val33Ala), gnomAD 1-22078576-T-C, CADD 24.60, PolyPhen-2 0.31
- V33V (p.Val33Val), gnomAD 1-22078577-A-G, CADD 9.71
- P34L (p.Pro34Leu), rs1645575465, ClinGen CA338912393, ClinVar RCV001765071, Ensembl rs1645575465, AlphaMissense 1.00, MetaLR 0.73, Uncertain significance, not provided
- P34Q (p.Pro34Gln), rs1645575465, ClinGen CA338912398, cosmic curated COSV10021, ClinVar RCV001312069, AlphaMissense 1.00, MetaLR 0.73, Conflicting interpretations, CDC42-related disorder; not provided
- P34S (p.Pro34Ser), gnomAD 1-22078578-C-T, CADD 25.20, PolyPhen-2 0.55
- P34P (p.Pro34Pro), rs776809649, gnomAD 1-22078580-G-A, CADD 6.25
- T35N (p.Thr35Asn), cosmic curated COSV10813, MetaLR 0.89, MetaSVM 1.09
- T35T (p.Thr35Thr), rs761795033, gnomAD 1-22078583-T-A, CADD 15.30
- V36F (p.Val36Phe), gnomAD rs1216194784, CADD 33.00, PolyPhen-2 0.98
- V36V (p.Val36Val), gnomAD 1-22081724-T-A, CADD 15.70
- F37L (p.Phe37Leu), gnomAD 1-22081722-GT-G, CADD 32.00
- F37F (p.Phe37Phe), gnomAD 1-22081727-T-C, CADD 12.30
- D38N (p.Asp38Asn), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, MetaLR 0.61, MetaSVM 0.41, Variant assessed as somatic; moderate impact.
- D38E (p.Asp38Glu), gnomAD 1-22078774-G-GGTG, CADD 18.50
- D38D (p.Asp38Asp), gnomAD 1-22078779-C-T, CADD 12.00
- N39K (p.Asn39Lys), rs762721731, gnomAD 1-22078749-G-GA, CADD 19.40
- N39I (p.Asn39Ile), gnomAD 1-22078749-GA-G, CADD 18.90
- N39H (p.Asn39His), gnomAD 1-22078753-A-C, CADD 19.60
- N39N (p.Asn39Asn), gnomAD 1-22078755-T-C, CADD 17.80
- N39T (p.Asn39Thr), gnomAD 1-22078807-CA-C, CADD 10.90
- N39S (p.Asn39Ser), rs1384009146, gnomAD 1-22078811-A-G, CADD 12.50
- Y40Y (p.Tyr40Tyr), rs773477556, gnomAD 1-22081736-T-C, CADD 10.40
- A41T (p.Ala41Thr), NCI-TCGA Cosmic COSV5966, cosmic curated COSV59662, MetaLR 0.35, MetaSVM -0.18, Variant assessed as somatic; moderate impact.
- A41V (p.Ala41Val), gnomAD 1-22081738-C-T, CADD 24.90, PolyPhen-2 0.17
- A41A (p.Ala41Ala), gnomAD 1-22081739-A-G, CADD 13.40
- V42G (p.Val42Gly), cosmic curated COSV10021
- V42I (p.Val42Ile), rs1057518022, ClinGen CA16042336, ClinVar RCV000414468, Ensembl rs1057518022, AlphaMissense 0.57, MetaLR 0.60, Likely pathogenic, not provided
- V42D (p.Val42Asp), gnomAD 1-22078766-T-A, CADD 17.30
- V42V (p.Val42Val), gnomAD 1-22078767-C-T, CADD 17.10
- T43T (p.Thr43Thr), rs762369675, gnomAD 1-22078782-A-G, CADD 11.80
- T43S (p.Thr43Ser), gnomAD 1-22081741-TCA-T, CADD 32.00
- V44V (p.Val44Val), rs771636441, gnomAD 1-22081748-T-C, CADD 11.70
- M45T (p.Met45Thr), rs2522184429, ClinVar RCV004576073, cosmic curated COSV10021, CADD 22.60, PolyPhen-2 0.23, Uncertain significance, not provided
- I46T (p.Ile46Thr), rs1570024112, ClinGen CA338913502, ClinVar RCV000824997, Ensembl rs1570024112, AlphaMissense 0.90, MetaLR 0.52, Likely pathogenic, Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptoda
- G47S (p.Gly47Ser), gnomAD 1-22078774-G-A, CADD 19.80
- G47D (p.Gly47Asp), rs927977264, gnomAD 1-22078775-G-A, CADD 19.40
- G47A (p.Gly47Ala), rs927977264, gnomAD 1-22078775-G-C, CADD 19.00
- G47V (p.Gly47Val), rs927977264, gnomAD 1-22078775-G-T, CADD 18.90
- G47G (p.Gly47Gly), rs991706001, gnomAD 1-22078776-T-C, CADD 20.40
- G48E (p.Gly48Glu), cosmic curated COSV59662, MetaLR 0.58, MetaSVM 0.22
- G48V (p.Gly48Val), gnomAD 1-22078784-G-T, CADD 17.60
- G48G (p.Gly48Gly), rs1461069254, gnomAD 1-22078785-G-T, CADD 17.60
- E49K (p.Glu49Lys), gnomAD rs1156458920, MetaLR 0.23, MetaSVM -0.69
- P50H (p.Pro50His), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- P50Q (p.Pro50Gln), Ensembl rs1645610224, CADD 24.30, PolyPhen-2 0.97
- P50P (p.Pro50Pro), rs1406702804, gnomAD 1-22081766-A-G, CADD 13.30
- Y51H (p.Tyr51His), rs1401679863, NCI-TCGA Cosmic COSV5966, cosmic curated COSV59663, gnomAD rs1401679863, AlphaMissense 0.83, MetaLR 0.56, Variant assessed as somatic; moderate impact.
- Y51N (p.Tyr51Asn), gnomAD 1-22081767-T-A, CADD 24.80, PolyPhen-2 0.28
- T52N (p.Thr52Asn), gnomAD 1-22081771-C-A, CADD 19.90, PolyPhen-2 0.30
- G54* (p.Gly54Ter), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, Variant assessed as somatic; high impact.
- G54E (p.Gly54Glu), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, MetaLR 0.58, MetaSVM 0.22, Variant assessed as somatic; moderate impact.
- G54R (p.Gly54Arg), rs751156562, gnomAD 1-22078801-G-A, CADD 10.10
- G54W (p.Gly54Trp), gnomAD 1-22078801-G-T, CADD 9.63
- L55I (p.Leu55Ile), gnomAD 1-22081779-C-A, CADD 24.80, PolyPhen-2 0.60
- F56L (p.Phe56Leu), gnomAD 1-22078785-GT-G, CADD 18.10
- D57E (p.Asp57Glu), cosmic curated COSV10021, MetaLR 0.80, MetaSVM 0.84
- D57Y (p.Asp57Tyr), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, CADD 32.00, PolyPhen-2 1.00, Variant assessed as somatic; moderate impact.
- D57D (p.Asp57Asp), rs774711630, gnomAD 1-22081787-T-C, CADD 12.90
- T58A (p.Thr58Ala), cosmic curated COSV59661, MetaLR 0.84, MetaSVM 0.91
- T58N (p.Thr58Asn), gnomAD 1-22081789-C-A, CADD 26.70, PolyPhen-2 0.99
- A59S (p.Ala59Ser), rs1374842999, gnomAD 1-22078798-G-T, CADD 7.33
- A59V (p.Ala59Val), gnomAD 1-22078799-C-T, CADD 14.70
- A59P (p.Ala59Pro), gnomAD 1-22081791-G-C, CADD 31.00, PolyPhen-2 0.91
- A59E (p.Ala59Glu), gnomAD 1-22081791-GC-G, CADD 33.00
- A59T (p.Ala59Thr), gnomAD 1-22081791-G-A, CADD 29.50, PolyPhen-2 0.75
- A59A (p.Ala59Ala), gnomAD 1-22081793-A-G, CADD 23.60
- G60C (p.Gly60Cys), gnomAD 1-22078852-G-T, CADD 16.10
- G60R (p.Gly60Arg), gnomAD 1-22081794-G-A, CADD 37.00, PolyPhen-2 1.00
- G60G (p.Gly60Gly), gnomAD 1-22086440-G-A, CADD 16.10
- Q61H (p.Gln61His), cosmic curated COSV10646, MetaLR 0.72, MetaSVM 0.41
- Q61K (p.Gln61Lys), gnomAD 1-22078756-C-A, CADD 16.30
- Q61Q (p.Gln61Gln), rs543598761, gnomAD 1-22078758-G-A, CADD 16.50
- Q61R (p.Gln61Arg), rs1645577572, gnomAD 1-22078808-A-G, CADD 14.10
- Q61* (p.Gln61Ter), rs1186628830, gnomAD 1-22078822-C-T, CADD 17.10
- Q61E (p.Gln61Glu), rs1186628830, gnomAD 1-22078822-C-G, CADD 15.70
- E62D (p.Glu62Asp), NCI-TCGA Cosmic COSV5966, cosmic curated COSV59661, Variant assessed as somatic; moderate impact.
- E62Q (p.Glu62Gln), rs2522220905, ClinGen CA338906488, ClinVar RCV002462755, Uncertain significance, not provided
- E62* (p.Glu62Ter), rs1205809656, gnomAD 1-22078834-G-T, CADD 17.70
- E62K (p.Glu62Lys), rs1205809656, gnomAD 1-22078834-G-A, CADD 17.20
- E62V (p.Glu62Val), gnomAD 1-22078835-A-T, CADD 18.30
- E62R (p.Glu62Arg), gnomAD 1-22086441-CA-C, CADD 33.00
- E62E (p.Glu62Glu), gnomAD 1-22086446-G-A, CADD 9.46
- D63V (p.Asp63Val), NCI-TCGA Cosmic COSV5966, cosmic curated COSV59662, MetaLR 0.70, MetaSVM 0.51, Variant assessed as somatic; moderate impact.
- D63Y (p.Asp63Tyr), gnomAD 1-22078825-G-T, CADD 17.60
- D63G (p.Asp63Gly), gnomAD 1-22086448-A-G, CADD 32.00, PolyPhen-2 0.99
- Y64C (p.Tyr64Cys), rs864309721, ClinGen CA278804, ClinVar RCV000203307, ClinVar RCV000489915, AlphaMissense 0.99, MetaLR 0.81, Pathogenic/Likely pathogenic, Inborn genetic diseases; Macrothrombocytopenia-lymphedema-developmental delay-fa
- Y64S (p.Tyr64Ser), rs864309721, ClinVar RCV004573105, AlphaMissense 0.99, MetaLR 0.81, Pathogenic, not provided
- D65V (p.Asp65Val), NCI-TCGA Cosmic COSV5966, cosmic curated COSV59663, MetaLR 0.82, MetaSVM 0.96, Variant assessed as somatic; moderate impact.
- D65Y (p.Asp65Tyr), gnomAD 1-22086453-G-T, CADD 32.00, PolyPhen-2 0.99
- D65G (p.Asp65Gly), gnomAD 1-22086454-A-G, CADD 29.10, PolyPhen-2 0.49
- R66G (p.Arg66Gly), rs797044870, ClinGen CA204641, ClinVar RCV000190678, ClinVar RCV000601199, CADD 29.90, PolyPhen-2 0.89, Pathogenic, Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptoda
- R66K (p.Arg66Lys), NCI-TCGA Cosmic COSV5966, cosmic curated COSV59662, Variant assessed as somatic; moderate impact.
- R66R (p.Arg66Arg), gnomAD 1-22078773-G-A, CADD 19.20
- R66T (p.Arg66Thr), rs763721408, gnomAD 1-22078793-G-C, CADD 17.50
- R66I (p.Arg66Ile), gnomAD 1-22078820-G-T, CADD 17.70
- L67L (p.Leu67Leu), gnomAD 1-22086461-A-G, CADD 12.10
- R68* (p.Arg68Ter), cosmic curated COSV59662, gnomAD rs1645663269, CADD 37.00
- R68Q (p.Arg68Gln), rs1553196096, ClinGen CA338906652, ClinVar RCV000519757, ClinVar RCV001291423, AlphaMissense 1.00, MetaLR 0.64, Pathogenic, not provided; Macrothrombocytopenia-lymphedema-developmental delay-facial dysmor
- R68R (p.Arg68Arg), gnomAD 1-22086462-C-A, CADD 13.30
- R68L (p.Arg68Leu), gnomAD 1-22086463-G-T, CADD 31.00, PolyPhen-2 0.92
- P69L (p.Pro69Leu), rs1645663343, ClinVar RCV004560449, NCI-TCGA Cosmic COSV1002, cosmic curated COSV10021, AlphaMissense 0.99, MetaLR 0.62, Uncertain significance, Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptoda
- P69Q (p.Pro69Gln), Ensembl rs1645663343, MetaLR 0.62, MetaSVM 0.46
- P69P (p.Pro69Pro), rs368234616, gnomAD 1-22086467-G-A, CADD 11.60
- L70P (p.Leu70Pro), cosmic curated COSV59662, MetaLR 0.57, MetaSVM 0.28
- L70L (p.Leu70Leu), rs1434687808, gnomAD 1-22086470-G-C, CADD 11.10
- S71I (p.Ser71Ile), cosmic curated COSV10646, MetaLR 0.66, MetaSVM 0.63
- S71L (p.Ser71Leu), gnomAD 1-22078793-GAAGT-, CADD 17.10
- S71A (p.Ser71Ala), gnomAD 1-22078813-T-G, CADD 8.92
- S71C (p.Ser71Cys), gnomAD 1-22078814-C-G, CADD 12.70
- S71S (p.Ser71Ser), gnomAD 1-22078815-C-A, CADD 13.80
- S71P (p.Ser71Pro), gnomAD 1-22078828-T-C, CADD 18.50
- S71Y (p.Ser71Tyr), gnomAD 1-22078844-C-A, CADD 10.90
- Y72Y (p.Tyr72Tyr), rs1645663430, gnomAD 1-22086476-T-C, CADD 10.60
- P73L (p.Pro73Leu), NCI-TCGA Cosmic COSV5966, cosmic curated COSV59663, MetaLR 0.66, MetaSVM 0.63, Variant assessed as somatic; moderate impact.
- P73T (p.Pro73Thr), gnomAD 1-22078864-C-A, CADD 6.71
- P73H (p.Pro73His), gnomAD 1-22078865-C-A, CADD 10.80
- P73P (p.Pro73Pro), gnomAD 1-22078866-T-C, CADD 13.70
- Q74K (p.Gln74Lys), rs1203336455, gnomAD 1-22078846-C-A, CADD 13.00
- Q74E (p.Gln74Glu), rs1203336455, gnomAD 1-22078846-C-G, CADD 12.80
- Q74H (p.Gln74His), rs761966253, gnomAD 1-22078848-A-T, CADD 8.96
- Q74Q (p.Gln74Gln), rs761966253, gnomAD 1-22078848-A-G, CADD 9.35
- T75A (p.Thr75Ala), rs765164792, gnomAD 1-22078867-A-G, CADD 14.10
- T75S (p.Thr75Ser), rs765164792, gnomAD 1-22078867-A-T, CADD 13.80
- T75K (p.Thr75Lys), gnomAD 1-22078868-C-A, CADD 15.50
- T75R (p.Thr75Arg), rs1417319887, gnomAD 1-22078868-C-G, CADD 15.40
- T75T (p.Thr75Thr), gnomAD 1-22078869-A-C, CADD 17.40
- D76G (p.Asp76Gly), TOPMed rs1645663483, Uncertain significance, not provided
- D76V (p.Asp76Val), rs1645663483, ClinGen CA338906764, ClinVar RCV003458288, AlphaMissense 0.98, MetaLR 0.72, Likely pathogenic, Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptoda
- D76D (p.Asp76Asp), rs1645663510, gnomAD 1-22086488-T-C, CADD 11.70
- V77I (p.Val77Ile), ESP rs372264403
Public CDC42 analysis runs
- CDC42 analysis run — CDC42 (319 variants) — completed 2026-08-22